VOR vs. SYRE, UPB, STOK, VERV, PRAX, VALN, CRMD, MLYS, NUVB, and ORIC
Should you be buying Vor Biopharma stock or one of its competitors? The main competitors of Vor Biopharma include Spyre Therapeutics (SYRE), Upstream Bio (UPB), Stoke Therapeutics (STOK), Verve Therapeutics (VERV), Praxis Precision Medicines (PRAX), Valneva (VALN), CorMedix (CRMD), Mineralys Therapeutics (MLYS), Nuvation Bio (NUVB), and Oric Pharmaceuticals (ORIC). These companies are all part of the "pharmaceutical products" industry.
Vor Biopharma vs. Its Competitors
Vor Biopharma (NYSE:VOR) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.
Vor Biopharma presently has a consensus price target of $6.07, indicating a potential upside of 191.67%. Spyre Therapeutics has a consensus price target of $53.40, indicating a potential upside of 213.01%. Given Spyre Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Spyre Therapeutics is more favorable than Vor Biopharma.
In the previous week, Vor Biopharma had 1 more articles in the media than Spyre Therapeutics. MarketBeat recorded 3 mentions for Vor Biopharma and 2 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.00 beat Vor Biopharma's score of -0.02 indicating that Spyre Therapeutics is being referred to more favorably in the news media.
97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 0.5% of Vor Biopharma shares are owned by insiders. Comparatively, 15.4% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Vor Biopharma's return on equity of 0.00% beat Spyre Therapeutics' return on equity.
Spyre Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.
Vor Biopharma has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the S&P 500.
Summary
Spyre Therapeutics beats Vor Biopharma on 7 of the 12 factors compared between the two stocks.
Get Vor Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vor Biopharma Competitors List
Related Companies and Tools
This page (NYSE:VOR) was last updated on 8/26/2025 by MarketBeat.com Staff
MarketBeat All Access